search icon
      blog search icon

      NovaBay (NBY) Surpasses Resistance in After-MarketTrading

      By Wasim Omar

      Published on

      May 19, 2023

      7:15 AM UTC

      NovaBay (NBY) Surpasses Resistance in After-MarketTrading

      NovaBay Pharmaceuticals, Inc. (NYSE: NBY), a biopharmaceutical company specializing in eyecare, skincare, and wound care products, experiences an astonishing after-market price surge.

      While the stock remained stable throughout the day, it soared an impressive 42% after hours. This unexpected spike captures attention and raises speculation about the driving factors behind NovaBay Pharmaceuticals’ remarkable after-market performance.

      NBY Bulls Optimistic After Resistance Line Breakthrough

      NovaBay Pharmaceuticals, Inc. (NBY) witnessed a remarkable surge in its stock price during after-hours trading, climbing from $0.70 to over $1. Traders are closely monitoring resistance levels, with the potential for the stock to reach $1.30, $1.70, and possibly even $3.30 when the market opens.

      While some traders may cash out to recover losses, others believe this is just the beginning of a larger upward movement, potentially yielding over 400% gains. Speculation is growing about an upcoming announcement that could unveil significant positive developments, with expectations high for the following week.

      Positive NovaBay Pharmaceuticals Results

      NBY experienced a price surge due to a positive quarterly report. The company saw increased revenue from its Avenova eyecare products, driven by higher sales and growing interest. They also benefited from cost reductions in sales and marketing through digital optimization, leading to a margin improvement of 62%, compared to the prior year’s 55%.

      NBY has been focusing on expanding its product portfolio and recently introduced new branded products, including a solution for relieving psoriasis symptoms. In the wound care segment, a significant order was shipped to their partner in China. The company expects the recent financing and strong sales to contribute to its goal of achieving profitability.


      NovaBay Pharmaceuticals experiences a staggering 42% after-market price jump, sparking speculation about upcoming positive developments. Traders monitor resistance levels, anticipating potential gains of up to $3.30. NBY’s positive quarterly report reveals increased revenue and cost reductions, supporting the company’s goal of achieving profitability.

      More From Stocks telegraph